Tuesday, Nov 19, 2019 8:00a -
Wednesday, Nov 20, 2019 5:00p
Revere Hotel Boston Common
200 Stuart Street
Boston, Massachusetts 02116
Lectures & Conferences
As CRISPR genome editing struggles to overcome key specificity and delivery challenges in its pursuit to realize therapeutic applications, the 1st RNA Editing Summit 2019 accelerates the translation and commercialization of RNA editing for an array of research and therapeutic applications.
As the therapeutic potential of RNA editing explodes, discover the fundamental mechanisms of RNA editing, such as recruiting endogenous ADARs with encodable guideRNAs, and learn about the novel approaches being developed to precisely and efficiently deliver intended RNA edits.
Join RNA, functional genomic, cell biology and immuno-oncology experts from large pharma, biotech and academia at the 1st RNA Editing Summit 2019 in the pursuit of translating emerging RNA editing mechanisms into therapeutic reality.
Conference Only (Industry Pricing) - Early Bird 1: USD 2199.0,
Conference Only (Industry Pricing) - Early Bird 1: USD 2399.0,
Conference Only (Industry Pricing) - Early Bird 1: USD 2599.0,
Conference Only (Industry Pricing) - Standard: USD 2899.0,
Conference Only (Academic) - Early Bird 1: USD 1399.0,
Conference Only (Academic) - Early Bird 1: USD 1499.0,
Conference Only (Academic) - Early Bird 1: USD 1599.0,
Conference Only (Academic) - Standard: USD 1799.0
Speakers: Eli Eisenberg,Professor Tel, Aviv University, Maria Montiel Gonzalez Scientist, RNA editing platform, Beam Therapeutics, Erez Levanon, Professor, Bar-Ilan University, Gene Yeo, Professor, University of California, San Diego, Nina Papavasiliou, University Professor and Division Head German Cancer Research Center, Heidelberg, Germany Visiting Professor, Rockefeller University, New York, Jonathan Gootenberg, McGovern Fellow, McGovern Institute for Brain Research, MIT, Dr. Joshua Rosenthal, Senior Scientist, Marine Biological Laboratory, Omar Abudayyeh, McGovern Fellow, the McGovern Institute for Brain Research MIT, Thorsten Stafforst, Professor, University of Tuebingen, Yi-Tao Yu, Principal Investigator and Professor, University of Rochester Medical Centre, Hyo Min Park, CTO and co-founder, GenEdit, Scott Ribich, Vice President, Biology, Accent Therapeutics, U. Thomas Meier, Professor, Albert Einstein College of Medicine, Jeffrey Ostrove, CEO and Director, Locana, Alan Herbert, Founder and Head of Discovery, InsideOutBio, Francois Vigneault, Co-Founder, President and CEO, Shape Therapeutics, Jin Billy Li, Associate Professor, Stanford University, Michael Jantsch, Professor Medical, University of Vienna, Oliver Rausch, Chief Scientific Officer, STORM Therapeutics, David Rodman, Executive VP RandD, ProQR, Andrew Fraley, Founder and SVP Technology, Korro Bio, Prashant Mali, Assistant Professor, Bioengineering, University of San Diego